A case report of severe hyponatremia secondary to Paxlovid-induced SIADH

被引：2

作者：

Mohamed, Sarah ^{[1
]}

Mostafa, Mostafa Reda ^{[2
]}

Eid, Mohamed Magdi ^{[2
]}

Abdelqadir, Yossef Hassan ^{[3
]}

Abdelghafar, Yomna Ali ^{[3
]}

Swed, Sarya ^{[4
]}

Jahshan, Bishara ^{[2
]}

El-Radi, Waddah Abd ^{[2
]}

机构：

[1] Cairo Univ, Sch Med, Giza, Egypt

[2] Rochester Reg Unity Hosp, Dept Med, Rochester, NY USA

[3] Alexandria Univ, Fac Med, Alexandria, Egypt

[4] Aleppo Univ, Fac Med, Aleppo, Syria

来源：

CLINICAL CASE REPORTS | 2023年 / 11卷 / 09期

关键词：

COVID-19; hyponatremia; nirmatrelvir-ritonavir; PAXLOVID; SARS-CoV-2; virus; SIADH;

D O I：

10.1002/ccr3.7860

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nirmatrelvir-ritonavir (Paxlovid) is a brand-new oral antiviral medication for treating mild to severe COVID-19. The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for ritonavir-nirmatrelvir on December 22, 2021, to treat COVID-19. We describe a case of mild COVID-19 infection who developed severe hyponatremia following the administration of Paxlovid. Clinical and laboratory evaluations suggest SIADH, likely secondary to Paxlovid. The potential side effects of this medication still require further study.

引用

收藏

页数：5

相关论文

共 17 条

[1] The syndrome of inappropriate antidiuresis (SIAD) [J].

Cuesta, Martin ;

Thompson, C. J. .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 30 (02) :175-187

[2]

FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVIDTM, FULL FACT SHEET HEAL

[3] Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study [J].

Falhammar, Henrik ;

Lindh, Jonatan D. ;

Calissendorff, Jan ;

Skov, Jakob ;

Nathanson, David ;

Mannheimer, Buster .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 59 :65-69

[4] Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis [J].

Gabriel Ruiz-Sanchez, Jorge ;

Nunez-Gil, Ivan J. ;

Cuesta, Martin ;

Rubio, Miguel A. ;

Maroun-Eid, Charbel ;

Arroyo-Espliguero, Ramon ;

Romero, Rodolfo ;

Manuel Becerra-Munoz, Victor ;

Uribarri, Aitor ;

Feltes, Gisela ;

Trabattoni, Daniela ;

Molina, Maria ;

Garcia Aguado, Marcos ;

Pepe, Martino ;

Cerrato, Enrico ;

Alfonso, Emilio ;

Castro Mejia, Alex Fernando ;

Raposeiras Roubin, Sergio ;

Buzon, Luis ;

Bondia, Elvira ;

Marin, Francisco ;

Lopez Pais, Javier ;

Abumayyaleh, Mohammad ;

D'Ascenzo, Fabrizio ;

Rondano, Elisa ;

Huang, Jia ;

Fernandez-Perez, Cristina ;

Macaya, Carlos ;

de Miguel Novoa, Paz ;

Calle-Pascual, Alfonso L. ;

Estrada Perez, Vicente ;

Runkle, Isabelle .

FRONTIERS IN ENDOCRINOLOGY, 2020, 11

[5] Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 [J].

Hammond, Jennifer ;

Leister-Tebbe, Heidi ;

Gardner, Annie ;

Abreu, Paula ;

Bao, Weihang ;

Wisemandle, Wayne ;

Baniecki, MaryLynn ;

Hendrick, Victoria M. ;

Damle, Bharat ;

Simon-Campos, Abraham ;

Pypstra, Rienk ;

Rusnak, James M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) :1397-1408

[6] Age and gender as risk factors for hyponatremia and hypernatremia [J].

Hawkins, RC .

CLINICA CHIMICA ACTA, 2003, 337 (1-2) :169-172

[7] Hyponatremia Independent of Osteoporosis is Associated with Fracture Occurrence [J].

Kinsella, Sinead ;

Moran, Sarah ;

Sullivan, Miriam O. ;

Molloy, Michael G. M. ;

Eustace, Joseph A. .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (02) :275-280

[8]

Laczi Ferenc, 2008, Orvosi Hetilap, V149, P1347, DOI 10.1556/OH.2008.28409

[9] Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series [J].

Lepage, Marc-Antoine ;

Rozza, Nicholas ;

Kremer, Richard ;

Grunbaum, Ami .

CLINICAL TOXICOLOGY, 2021, 59 (07) :644-647

[10] HYPONATREMIA IN A NURSING-HOME POPULATION [J].

MILLER, M ;

MORLEY, JE ;

RUBENSTEIN, LZ .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1995, 43 (12) :1410-1413